Centre of Excellence for Research on Environment, Health and Aging

Innovation Impact

Innovation Impact

CEREHA intends to substantially improve its innovation potential by improving the way IPR (Intellectual Property Rights) are addressed currently, manage in a more efficient manner its relations with researchers and external counterparts such as the industry or commercial partners, and shorten by 1/3 the “time to result” of knowledge exploitation, which is today subject to strong delays due to both internal administrative procedures, and to processes related to national or international patenting regulations and practice.

CEREHA’s plans to intervene on IPR’s will be contained in a highly strategic document, defined as a
Strategic Intellectual Property development plan. Whereas this builds upon the current practices in use at CEREHA to deal with the exploitation of new knowledge, it will evolve along the following lines:

  • More stimulating relationships and impulse to CEREHA researchers that is able to generate potentially exploitable results
  • Smoother procedures and more decentralised financial autonomy at the level of departments and research units to start mechanisms for the protection of knowledge or to negotiate agreements with external partners (in particular the industry)
  • Increased support and consolidation of the TTO (Technology Transfer Office) know-how to handle exploitation purposes and joint ventures or other types of agreements with industrial partners.

As of today at new IPR at CEREHA can be generated by the following processes:

  • Whenever a new IPR is identified ("The disclosure phase") a specific committee (composed of externals reviewers/ experts) is formed to evaluate the technology. Then an IPR expert evaluates the specific IPR value in regards to freedom of operation, the potential commercialisation and patentability.
  • The committee will not approve of patent applications for those technologies which are difficult to prove enablement, which are obvious or easily anticipated, too narrow, referred to too small market or too crowded market.
  • Following positive recommendations of the Committee and IPR evaluator CEREHA through its Technology Transfer Office (TTO) - known as Gavish − Galilee Bioapplications Ltd. - applies for a new patent application (usually a provisional patent application). Assuming a provisional patent application was filled, then within a period of 12 months a regular US or Patent Cooperation Treaty (PCT) application is filled. During the PCT period route of 30 months the application undergoes further search and preliminary examination. This period gives MIGAL/Gavish more time to ascertain the patentability and filling in applications with other foreign (national) patent offices which can help determining the invention's "robustness". The 30 months period is the most favourable period for commercialisation. During this period the invention is relevant to its potential market and cost for patenting is relatively low.
  • National applications are very expensive (30-60K Euros). Only patent applications, which are subjected to commercialisation process, are supported by MIGAL's internal funds for the purposes of national applications. Whenever a patent application is allowed, then the management takes care of paying annuities maintenance fees.

Our industrial partners are excited about the opportunity to collaborate with CEREHA considering the following:

  • CEREHA is dealing with cutting edge technologies.
  • CEREHA 's investigators hold unique expertise in their research fields.
  • CEREHA research portfolio has the potential for breakthrough discoveries.
  • New emerging fields in biotechnology and the environmental disciplines are part of CEREHA's research scope.
  • CEREHA enjoys the collaboration with industry by closing the gap between the market's needs and applied science, generating income and being able to promote economic growth as well as rewarding, retaining and recruiting new researchers.
  • Such industrial collaboration can be diverted for the benefit of Sponsored Based Research. Industry finances all research activities and is considered to be the IPR holder. In some cases the results can be shared between industry and MIGAL. In those cases MIGAL still benefits from research costs, license fees, milestones payments and equity which are being paid by industry: Co-Development: When research is implemented by both, industry and MIGAL. Rewards of MIGAL shall be similar to the above. Usually, no IPR rights, no milestones payments. In this track instead of royalties, a model of profit share is created. Split the output: When each party fulfils the parts of its expertise Outcome is divided between industry and MIGAL. MIGAL can delegate its share to a third party and receive royalties from both industry and the third party.